Using Genomic Biomarkers to Predict Patient Prognosis and Treatment Response in Gastric Cancer

摘要: Research over the past decade has shown that genomic biomarkers can predict cancer susceptibility in otherwise healthy patients, and when applied to tumors stratify patients into subgroups exhibiting distinct prognostic treatment response outcomes. Genomic germline DNAs of also establish pharmacogenetic profiles individualize drug selection dosing. Much this molecular knowledge been facilitated by unprecedented wave new technologies greatly enhanced analysis genomes, including DNA microarrays, next-generation sequencing, large-scale functional genetic screens. Integration these with standard clinical laboratory tests is logical next step care treatment, where individualized genome will allow tailoring treatments provide maximum benefit individual. In chapter, we describe current state regarding gastric (GC).